Semaglutide in people with HIV-associated lipohypertrophy

Lancet Diabetes Endocrinol. 2024 Aug;12(8):504-505. doi: 10.1016/S2213-8587(24)00162-1. Epub 2024 Jul 1.

Authors

Y Joseph Hwang¹, Todd T Brown¹, Jacqueline Capeau²

Affiliations

¹ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Inserm UMR_S938, Centre de Recherche Saint-Antoine, Sorbonne Université, Paris 75012, France; Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Paris, France. Electronic address: jacqueline.capeau@inserm.fr.

PMID: 38964354
DOI: 10.1016/S2213-8587(24)00162-1

No abstract available

MeSH terms

Glucagon-Like Peptides* / adverse effects
Glucagon-Like Peptides* / therapeutic use
HIV Infections / complications
HIV Infections / drug therapy
HIV-Associated Lipodystrophy Syndrome / chemically induced
HIV-Associated Lipodystrophy Syndrome / drug therapy
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use

Substances

semaglutide
Glucagon-Like Peptides
Hypoglycemic Agents